Diagnostic dilemma: Treatment outcomes of tuberculosis patients with inconsistent rifampicin susceptibility

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 3, 2014, Pages 357-362

  Pang, Y ^a   Ruan, Y Z ^a   Zhao, J ^a   Chen, C ^a   Xu, C H ^a   Su, W ^a   Huan, S T ^b   Li, R Z ^a   Zhao, Y L ^a   Chin, D P ^b   Wang, L X ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Clinical outcome; Rifampicin; Tuberculosis

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; DNA MICROARRAY; DRUG EFFECTS; DRUG SUBSTITUTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIOLOGICAL TECHNIQUES; DRUG RESISTANCE, BACTERIAL; DRUG SUBSTITUTION; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIFAMPIN; RISK FACTORS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84894274982     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0459     Document Type: Article

References (33)

1. Walls T, Shingadia D. The epidemiology of tuberculosis in Europe. Arch Dis Child 2007; 92: 726-729.
2. Pang Y, Song Y, Xia H, Zhou Y, Zhao B, Zhao Y. Risk factors and clinical phenotypes of Beijing genotype strains in tuberculosis patients in China. BMC Infect Dis 2012; 12: 354.
3. World Health Orgnization. Global tuberculosis report, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
4. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22: 167-173.
5. Heysell S K, Houpt E R. The future of molecular diagnostics for drug-resistant tuberculosis. Expert Rev Mol Diagn 2012; 12: 395-405.
6. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013; 57: 893-900.
7. Zhao Y, Wang L, Xu S, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366: 2161-2170.
8. Palomino J C. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2009; 56: 103-111.
9. Rüsch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692.
10. Hoek K G, Van Rie A, van Helden P D, Warren R M, Victor T C. Detecting drug-resistant tuberculosis: the importance of rapid testing. Mol Diagn Ther 2011; 15: 189-194.
11. Dorman S E, Chaisson R E. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 2007; 13: 295-298.
12. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
13. Mathema B, Kurepina N E, Bifani P J, Kreiswirth B N. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 2006; 19: 658-685.
14. Gillespie S H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002; 46: 267-274.
15. Ramaswamy S, Musser J M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle Lung Dis 1998; 79: 3-29.
16. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman M E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792.
17. Tortoli E, Marcelli F. Use of the INNO LiPA Rif.TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J Clin Microbiol Infect Dis 2007; 26: 51-55.
18. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48: 229-237.
19. Guo Y, Zhou Y, Wang C, et al. Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system. Int J Tuberc Lung Dis 2009; 13: 914-920.
20. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
21. Somoskovi A, Parsons L M, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001; 2: 164-168.
22. Almeida Da Silva P E, Palomino J C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011; 66: 1417-1430.
23. Van Deun A, Wright A, Zignol M, Weyer K, Rieder H L. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011; 15: 116-124.
24. Koser C U, Feuerriegel S, Summers D K, Archer J A, Niemann S. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 2012; 56: 6080-6087.
25. van den Boogaard J, Kibiki G S, Kisanga E R, Boeree M J, Aarnoutse R E. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53: 849-862.
26. Ginsberg A M, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007; 13: 290-294.
27. Faustini A, Hall A J, Perucci C A. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J 2005; 26: 503-510.
28. Centis R, Ianni A, Migliori G B. Evaluation of tuberculosis treatment results in Italy, report 1998. Tuberculosis section of the National AIPO Study Group on Infectious Disease and the SMIRA Group. Monaldi Arch Chest Dis 2000; 55: 293-298.
29. Ambrosetti M, Besozzi G, Codecasa L R, et al.; National AIPO 'Tuberculosis' Study Group. The Italian AIPO study on tuberculosis treatment results, report 1997. Monaldi Arch Chest Dis 1999; 54: 407-412.
30. Lambregts-van Weezenbeek C S B, Jansen H M, Nagelkerke N J D, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcome. Int J Tuberc Lung Dis 1998; 2: 288-295.
31. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
32. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 2009; 4: e6914.
33. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.